Page 2289 - Williams Hematology ( PDFDrive )

2264 Part XII: Hemostasis and Thrombosis Chapter 132: Thrombotic Microangiopathies 2265

37. Camous L, Veyradier A, Darmon M, et al: Macrovascular thrombosis in critically ill 68. Rizvi MA, Vesely SK, George JN, et al: Complications of plasma exchange in 71
patients with thrombotic micro-angiopathies. Intern Emerg Med 9:267, 2014. consecutive patients treated for clinically suspected thrombotic thrombocytopenic
38. Hawkins BM, Abu-Fadel M, Vesely SK, George JN: Clinical cardiac involvement in purpura-hemolytic-uremic syndrome. Transfusion 40:896, 2000.
thrombotic thrombocytopenic purpura: A systematic review. Transfusion 48:382, 2008. 69. Lim W, Vesely SK, George JN: The role of rituximab in the management of patients with
39. Hughes C, McEwan JR, Longair I, et al: Cardiac involvement in acute thrombotic acquired thrombotic thrombocytopenic purpura. Blood 125:1526, 2015.
thrombocytopenic purpura: Association with troponin T and IgG antibodies to 70. Westwood JP, Webster H, McGuckin S, et al: Rituximab for thrombotic thrombocy-
ADAMTS 13. J Thromb Haemost 7:529, 2009. topenic purpura: Benefit of early administration during acute episodes and use of pro-
40. Benhamou Y, Assie C, Boelle PY, et al: Development and validation of a predictive phylaxis to prevent relapse. J Thromb Haemost 11:481, 2013.
model for death in acquired severe ADAMTS13 deficiency-associated idiopathic 71. Hie M, Gay J, Galicier L, et al: Preemptive rituximab infusions after remission efficiently
thrombotic thrombocytopenic purpura: The French TMA Reference Center experi- prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood 124:204,
ence. Haematologica 97:1181, 2012. 2014.
41. Zini G, d’Onofrio G, Briggs C, et al: ICSH recommendations for identification, diagnos- 72. Carson KR, Evens AM, Richey EA, et al: Progressive multifocal leukoencephalopa-
tic value, and quantitation of schistocytes. Int J Lab Hematol 34:107, 2012. thy after rituximab therapy in HIV-negative patients: A report of 57 cases from the
42. Burns ER, Lou Y, Pathak A: Morphologic diagnosis of thrombotic thrombocytopenic Research on Adverse Drug Event and Reports project. Blood 113:4834, 2009.
purpura. Am J Hematol 75:18, 2004. 73. Bharat A, Xie F, Baddley JW, et al: Incidence and risk factors for progressive multifocal
43. Veyradier A, Obert B, Houllier A, et al: Specific von Willebrand factor-cleaving leukoencephalopathy among patients with selected rheumatic diseases. Arthritis Care
protease in thrombotic microangiopathies: A study of 111 cases. Blood 98:1765, 2001. Res (Hoboken) 64:612, 2012.
44. Bianchi V, Robles R, Alberio L, et al: Von Willebrand factor-cleaving protease 74. Lunel-Fabiani F, Masson C, Ducancelle A: Systemic diseases and biotherapies: Under-
(ADAMTS13) in thrombocytopenic disorders: A severely deficient activity is specific standing, evaluating, and preventing the risk of hepatitis B reactivation. Joint Bone
for thrombotic thrombocytopenic purpura. Blood 100:710, 2002. Spine 81:478, 2014.
45. Tsai HM: Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocy- 75. Aqui NA, Stein SH, Konkle BA, et al: Role of splenectomy in patients with refractory or
topenic purpura? Yes. J Thromb Haemost 1:625, 2003. relapsed thrombotic thrombocytopenic purpura. J Clin Apher 18:51, 2003.
46. Asada Y, Sumiyoshi A, Hayashi T, et al: Immunohistochemistry of vascular lesion in 76. Kappers-Klunne MC, Wijermans P, Fijnheer R, et al: Splenectomy for the treatment of
thrombotic thrombocytopenic purpura, with special reference to factor VIII related thrombotic thrombocytopenic purpura. Br J Haematol 130:768, 2005.
antigen. Thromb Res 38:469, 1985. 77. Katkhouda N, Hurwitz MB, Rivera RT, et al: Laparoscopic splenectomy: Outcome and
47. Hosler GA, Cusumano AM, Hutchins GM: Thrombotic thrombocytopenic purpura efficacy in 103 consecutive patients. Ann Surg 228:568, 1998.
and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy 78. Ferrara F, Annunziata M, Pollio F, et al: Vincristine as treatment for recurrent episodes
cases. Arch Pathol Lab Med 127:834, 2003. of thrombotic thrombocytopenic purpura. Ann Hematol 81:7, 2002.
48. Zomas A, Saso R, Powles R, et al: Red cell fragmentation (schistocytosis) after bone 79. Bobbio-Pallavicini E, Porta C, Centurioni R, et al: Vincristine sulfate for the treatment
marrow transplantation. Bone Marrow Transplant 22:777, 1998. of thrombotic thrombocytopenic purpura refractory to plasma-exchange. The Italian
49. Kanamori H, Takaishi Y, Takabayashi M, et al: Clinical significance of fragmented red Cooperative Group for TTP. Eur J Haematol 52:222, 1994.
cells after allogeneic bone marrow transplantation. Int J Hematol 77:180, 2003. 80. Bobbio-Pallavicini E, Porta C, Tacconi F, et al: Intravenous prostacyclin (as epopros-
50. Mannucci PM, Canciani MT, Forza I, et al: Changes in health and disease of the metal- tenol) infusion in thrombotic thrombocytopenic purpura. Four case reports and
loprotease that cleaves von Willebrand factor. Blood 98:2730, 2001. review of the literature. Italian Cooperative Group for Thrombotic Thrombocytopenic
51. Kremer Hovinga JA, Zeerleder S, Kessler P, et al: ADAMTS-13, von Willebrand factor Purpura. Haematologica 79:429, 1994.
and related parameters in severe sepsis and septic shock. J Thromb Haemost 5:2284, 81. Sagripanti A, Carpi A, Rosaia B, et al: Iloprost in the treatment of thrombotic microan-
2007. giopathy: Report of thirteen cases. Biomed Pharmacother 50:350, 1996.
52. Uemura M, Fujimura Y, Matsumoto M, et al: Comprehensive analysis of ADAMTS13 82. Dervenoulas J, Tsirigotis P, Bollas G, et al: Efficacy of intravenous immunoglobulin in
in patients with liver cirrhosis. Thromb Haemost 99:1019, 2008. the treatment of thrombotic thrombocytopaenic purpura. A study of 44 cases. Acta
53. Park YD, Yoshioka A, Kawa K, et al: Impaired activity of plasma von Willebrand factor- Haematol 105:204, 2001.
cleaving protease may predict the occurrence of hepatic veno-occlusive disease after 83. Anderson D, Ali K, Blanchette V, et al: Guidelines on the use of intravenous immune
stem cell transplantation. Bone Marrow Transplant 29:789, 2002. globulin for hematologic conditions. Transfus Med Rev 21:S9, 2007.
54. Nguyen L, Li X, Duvall D, et al: Twice-daily plasma exchange for patients with refrac- 84. Cataland SR, Jin M, Lin S, et al: Cyclosporin and plasma exchange in thrombotic
tory thrombotic thrombocytopenic purpura: The experience of the Oklahoma Registry, thrombocytopenic purpura: Long-term follow-up with serial analysis of ADAMTS13
1989 through 2006. Transfusion 48:349, 2008. activity. Br J Haematol 139:486, 2007.
55. Scully M, Hunt BJ, Benjamin S, et al: Guidelines on the diagnosis and management 85. Shortt J, Oh DH, Opat SS: ADAMTS13 antibody depletion by bortezomib in throm-
of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. botic thrombocytopenic purpura. N Engl J Med 368:90, 2013.
Br J Haematol 158:323, 2012. 86. Ahmad HN, Thomas-Dewing RR, Hunt BJ: Mycophenolate mofetil in a case of relapsed,
56. Zeigler ZR, Shadduck RK, Gryn JF, et al: Cryoprecipitate poor plasma does not improve refractory thrombotic thrombocytopenic purpura. Eur J Haematol 78:449, 2007.
early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin 87. Li GW, Rambally S, Kamboj J, et al: Treatment of refractory thrombotic thrombocy-
Apher 16:19, 2001. topenic purpura with N-acetylcysteine: A case report. Transfusion 54:1221, 2014.
57. Rock G, Anderson D, Clark W, et al: Does cryosupernatant plasma improve outcome in 88. Spiekermann K, Wormann B, Rumpf KW, Hiddemann W: Combination chemother-
thrombotic thrombocytopenic purpura? No answer yet. Br J Haematol 129:79, 2005. apy with CHOP for recurrent thrombotic thrombocytopenic purpura. Br J Haematol
58. Michael M, Elliott EJ, Craig JC, et al: Interventions for hemolytic uremic syndrome and 97:544, 1997.
thrombotic thrombocytopenic purpura: A systematic review of randomized controlled 89. Passweg JR, Rabusin M, Musso M, et al: Haematopoetic stem cell transplantation for
trials. Am J Kidney Dis 53:259, 2009. refractory autoimmune cytopenia. Br J Haematol 125:749, 2004.
59. Prowse C: Properties of pathogen-inactivated plasma components. Transfus Med Rev 90. Callewaert F, Roodt J, Ulrichts H, et al: Evaluation of efficacy and safety of the anti-
23:124, 2009. VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic
60. McCarthy LJ: Evidence-based medicine for apheresis: An ongoing challenge. Ther thrombocytopenic purpura. Blood 120:3603, 2012.
Apher Dial 8:112, 2004. 91. Cataland SR, Peyvandi F, Mannucci PM, et al: Initial experience from a double-blind,
61. Yarranton H, Cohen H, Pavord SR, et al: Venous thromboembolism associated with the placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic
management of acute thrombotic thrombocytopenic purpura. Br J Haematol 121:778, thrombocytopenic purpura. Am J Hematol 87:430, 2012.
2003. 92. O’Brien KL, Price TH, Howell C, Delaney M: The use of 50% albumin/plasma replace-
62. Allford SL, Harrison P, Lawrie AS, et al: Von Willebrand factor—Cleaving protease ment fluid in therapeutic plasma exchange for thrombotic thrombocytopenic purpura.
activity in congenital thrombotic thrombocytopenic purpura. Br J Haematol 111:1215, J Clin Apher 28:416, 2013.
2000. 93. Zhan H, Streiff MB, King KE, Segal JB: Thrombotic thrombocytopenic purpura at
63. del Rio-Garma J, Alvarez-Larran A, Martinez C, et al: Methylene blue-photoinacti- the Johns Hopkins Hospital from 1992 to 2008: Clinical outcomes and risk factors for
vated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic relapse. Transfusion 50:868, 2010.
purpura: A multicentric, prospective cohort study. Br J Haematol 143:39, 2008. 94. Bandarenko N, Brecher ME: United States Thrombotic Thrombocytopenic Purpura
64. Bobbio-Pallavicini E, Gugliotta L, Centurioni R, et al: Antiplatelet agents in thrombotic Apheresis Study Group (US TTP ASG): Multicenter survey and retrospective analysis
thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the of current efficacy of therapeutic plasma exchange. J Clin Apher 13:133, 1998.
Italian Cooperative Group for TTP. Haematologica 82:429, 1997. 95. Tsai H-M, Shulman K: Rituximab induces remission of cerebral ischemia caused by
65. Coppo P, Lassoued K, Mariette X, et al: Effectiveness of platelet transfusions after thrombotic thrombocytopenic purpura. Eur J Haematol 70:183, 2003.
plasma exchange in adult thrombotic thrombocytopenic purpura: A report of two 96. Sadler JE: Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic
cases. Am J Hematol 68:198, 2001. purpura. Blood 112:11, 2008.
66. Goel R, Ness PM, Takemoto CM, et al: Platelet transfusions in platelet consumptive 97. McClain RS, Terrell DR, Vesely SK, George JN: Plasma exchange complications
disorders are associated with arterial thrombosis and in-hospital mortality. Blood in patients treated for thrombotic thrombocytopenia purpura-hemolytic uremic
125:1470, 2015. syndrome: 2011 to 2014. Transfusion 54:3257, 2014.
67. Doerfler ME, Kaufman B, Goldenberg AS: Central venous catheter placement in 98. Kennedy AS, Lewis QF, Scott JG, et al: Cognitive deficits after recovery from throm-
patients with disorders of hemostasis. Chest 110:185, 1996. botic thrombocytopenic purpura. Transfusion 49:1092, 2009.

Kaushansky_chapter 132_p2253-2266.indd 2264 17/09/15 3:48 pm